NBIX News and Press, Neurocrine Biosciences Inc. From 03/26/21

Are These The Best Health Care Stocks To Buy Before April 2021? No matter the state of the world, the health care industry will likely continue to work towards improving our quality of life. With this being the case, it would make sense then that investors are turning to health ca...

Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day PR Newswire SAN DIEGO , March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Ap...

Shares of Neurocrine Biosciences (NASDAQ: NBIX) were jumping 12.5% higher as of 3:22 p.m. EDT on Thursday. The big gain came after it was announced that Neurocrine will replace O-I Glass in the S&P MidCap 400 Index . The addition of the biotech stock to the S&...

Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600 Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600 PR Newswire NEW YORK , March 24, 2021 /PRNewswire/ -- Neurocrine B...

Neurocrine Biosciences (NBIX) has jumped 9.6% after hours following news that it's moving into the S&P MidCap 400 index. It's replacing O-I Glass (OI), which is making its own move into the SmallCap 600; OI is more representative of the small-cap market space than mid-cap, S&P Dow Jon...

Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021 - Additional Positive Data from Phase II CAHlibrate Study - Real-World Data Highlight Impact of CAH in Adult and Pediatric Patients PR ...

Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31 st Annual Healthcare Conference at 4:...

Neurocrine announced that its Phase II INTERACT study of luvadaxistat failed to achieve its primary endpoint of easing the negative symptoms of schizophrenia. I expected this trial to fail, but the drug did hit a secondary endpoint related to cognition; cognitive impairment is a major...

Neurocrine Biosciences shares slide ([[NBIX]] -6.7%) after announcing that its investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet the primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseli...

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) - Negative Outcome on Primary Endpoint Measured by the Change...